COMMUNIQUÉS West-GlobeNewswire

SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences
23/06/2026
NORTH PALM BEACH, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company [...]
Premier Health of America Announces CCAA Proceedings
23/06/2026
MONTREAL, June 23, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” , or the “Company” ) announces proceedings under the Companies’ Creditors Arrangement Act (Canada) (the “CCAA”) [...]
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
23/06/2026
- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s premier academic [...]
TOMI Reports Accelerating SteraMist Adoption as Ebola Outbreaks and Global Biosecurity Threats Drive Preparedness Spending
23/06/2026
Growing demand reflects increasing investment in scalable decontamination technologies across healthcare, emergency response, and critical infrastructure sectors FREDERICK, Md., June 23, 2026 (GLOBE NEWSWIRE) -- TOMI [...]
Tria Federal Appoints Former CMS and IRS CIO Rajiv Uppal to Advisory Board
23/06/2026
ARLINGTON, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Tria Federal today announced the appointment of Rajiv Uppal, former Chief Information Officer of the Centers for Medicare & Medicaid Services (CMS) and the Internal [...]
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in [...]
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
23/06/2026
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026 ( [...]
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the [...]
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
23/06/2026
Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ [...]
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company [...]
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within [...]
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
23/06/2026
CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the [...]
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
ECM Therapeutics Receives FDA 510(k) Clearance for ECMT-100 WMD
23/06/2026
WARRENDALE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- ECM Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K253521) for ECMT-100 WMD, a flowable extracellular [...]
Fieldstone Bio, TerraCore, and MIT Awarded U.S. Department of Energy Contract to Accelerate Critical Mineral Discovery
23/06/2026
New field-deployable approach uses engineered microbial sensors and compact imaging to "read" gold, rare earth elements, nickel, and more, cutting assay turnaround from weeks to hours WOBURN, Mass., June 23, 2026 (GLOBE [...]
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
23/06/2026
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto [...]
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
23/06/2026
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second [...]

Pages